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Abstract 
Background: Colorectal cancer (CRC) is the third leading cause of death worldwide 
comprising ~8% of cancer deaths per year. The survival rates of metastatic CRC is 13% because 
of the lack of successful treatment due to a lack of understanding of the scope and environment 
of stage IV CRC.  
Materials and Methods: The transcripts of five normal colon mucosa tissue samples and 
their matched five stage IV CRC samples were chosen and analyzed from the dataset with the 
GEO Accession GSE50760. The Tuxedo Suite pipeline was used to determine the differentially 
expressed genes (DEGs) with a fold change cut off of ≥ 0.5 and ≤ -0.5 and a p value cut off of ≤ 
0.05. Using the the DEG list, PANTHER database was used for pathway enrichment. 
LncRNA2Target database was used to find associated long non coding RNAs (lncRNAs) of the 
genes of interest. The Integrated Genome Viewer (IGV) was used to visualize any mutations or 
variations among the genes of interest. DeepSEA was used to functionally predict any potential 
novel SNPs. Using literature along with the results from PANTHER, lncRNA2Target, and IGV a 
novel connection was deduced.   
Results: There were 5,303 DEGs. The Wnt pathway had the greatest portion of DEGs 
indicating pathway activity. Interestingly, a number of inhibitors of the Wnt pathway were also 
upregulated including WIF1 and SFRP4. LncRNA2Target analysis showed that HOTAIR, a 
lncRNA, has a number of target genes and effectively silenced all of its targets except for WIF1 
and CD82 in this dataset. WIF1, CD82, and SFRP4 has increased fold change values of 5.165, 
1.05, 2.121, respectively. Additionally, lncRNAs, UCA1 and CRNDE, were found to positively 
regulate WNT5A, WNT2 and WNT3 and were upregulated. Using the integrative genome 
viewer, 10 SNPs were found in WIF1, SFRP4, CD82, WNT5A, and UCA1 of which one was 
novel. The potentially novel SNP in CD82 was functionally predicted to create a binding site 
with ZBTB7A. Additionally, CDKN2A and CDKN2B were found to have decreased expression 
with a fold change value of -2.266.  
Discussion: One synonymous SNP was in WIF1 and CD82. The missense SNPs in 
SFRP4 and CD82 are likely causing protein dysfunction resulting in ill-inhibition of the WNT 
pathway and metastasis, respectively. The novel SNP was found in CD82 at the location 
chr11:44,619,242 in the 3’ untranslated region. Functional prediction showed that this SNP may 
create a binding site with ZBTB7A which may be repressing CD82 function. Although most of 
the SNPs found were recorded to result in synonymous codons, the prevalence and frequency of 
these SNPs in these vital genes requires further investigation to confirm whether if these SNPs 
are coincidental or if they are damaging. Moreover, it is also probable that WIF1 and SFRP4 
may be competing with UCA1 to exert their effects on WNT5A. CRNDE may also be competing 
to ultimately positively regulate WNT2 and WNT3. Together with the SNPs, HOTAIR may not 
be able to silence WIF1 and CD82, WIF1 and SFRP4 are ineffective in inhibiting the WNT 
ligands, the missense and the potentially novel SNPs in CD82 may be the cause for the lack of 
metastasis suppression. Finally, the downreglulation of CDKN2A and CDKN2B may be due to 
environmental and/or ethnic causes as shown in previous studies with Egyptian and Chinese 
CRC patients.  
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CHAPTER 1: INTRODUCTION 
1.1 Colorectal Cancer 
 1.1.1 Epidemiology and Statistics  
Colorectal cancer is the third leading cause of death worldwide and the fourth leading 
cause of death in the United States with 50,000 expected deaths in 2017 1,2. There is a lifetime 
risk of developing CRC of 4.7% for men and 4.4% for women. About 95% of CRC start as an 
adenocarcinomas. The remaining 5% of cases begin as carcinoids, sarcomas, lymphomas, or 
gastrointestinal stromal tumors (GIST). There is a 90.1% survival rate in patients that have 
localized CRC (Figure 1). This rate drops significantly to 71.2% when the cancer becomes 
regionalized and further drops to 13.5% when the cancer has metastasized. 
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Figure 1: CRC Statistics. A) Five-Year Survival Rates by Stage. The cancers that are caught 
within the first two stages generally have the greatest chance of survival with an average 
survival rate of 90.1%. As the cancer progresses, the survival rates decreases. When the cancer 
becomes regional or when the cancer spreads to the surrounding lymph nodes, the chance of 
survival drops to 71.2%. When the cancer metastasizes, the chance of survival drops 
dramatically to 13.5%. (Image Source Reference 3, Copyright: see appendix) 
 
 
1.1.2 Risk Factors and Prevention  
Some risk factors include lack of physical activity, a diet high in meats and low in fruits 
and vegetables, obesity, smoking, heavy alcohol use, old age, family history of CRC or 
inflammatory bowel disease (IBD) among others 1. Prevention measures include regular 
colonoscopies for polyp screenings, healthy lifestyle with a balanced diet and exercise, no 
smoking, limiting alcohol consumption, consuming adequate vitamins and minerals, and taking 
non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin or ibuprofen on a regular basis. 
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1.1.3 Symptoms and Diagnosis  
The symptoms of CRC can vary according to the location of the tumor. Tumors located 
on the right side of the colon typically have more space to grow so the cancer may be present for 
some time before symptoms appear 4. Additionally, right-sided tumors cause iron deficiency 
anemia which is the main cause of the symptoms. Symptoms can include fatigue, and shortness 
of breath. The left side of the colon is narrower than the right. Oftentimes a tumor occurring in 
the left side can cause an obstruction resulting in constipation, narrow stools, cramps, bloating, 
and blood in the stool. Other symptoms include changes in bowel habits, abdominal discomfort, 
unexplained weight loss, and others.  
Colorectal cancer is diagnosed with a colonoscopy followed by a confirmation via biopsy 
5. Following diagnosis a series of blood tests, diagnostic scans, and a physical exam are 
conducted for staging purposes. There are several biomarkers that are used to aid diagnosis in 
addition to lab tests and imaging 6. These biomarkers include carcinoembryonic antigen (CEA), 
microsatellite instability (MSI), K-RAS, PIK3CA, and BRAF. CEA is a protein marker that is 
often elevated in CRC and metastasis, however, an elevated CEA does not always indicate 
CRC7. A positive, elevated CEA is found in about 60% of CRC with metastasis cases. It has 
been shown that 30-50% of CRC cases have a mutated K-RAS gene. This is an important marker 
because a positive result indicates that the cancer is less likely to respond to anti-epidermal 
growth factor receptor (anti-EGFR) therapy. Additionally, high levels of K-RAS is associated 
with poor survival and high cancer aggressiveness.  
 
1.1.4 Colorectal Cancer Staging Guidelines 
There are five stages of CRC: Stage 0, I, II, III, IV, illustrated in Figure 2 8. Each one of 
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these stages has a certain protocol of treatment. Stage 0 is characterized by the limited growth of 
the cancer, in other words when the cancer has not grown outside of the lining of the colon. 
Treatment for stage 0 CRC is to remove any cancerous tissue usually during a colonoscopy. 
Surgery is typically not needed unless the tissue cannot be excised during the colonoscopy. Stage 
I cancer is characterized by the growth of the cancer to the inner layers of the colon. Treatment 
for stage I is to excise any cancerous tissue and if necessary, a partial colectomy may be 
performed. Stage II cancer is characterized by the growth of the cancer into the walls of the 
colon and to neighboring tissue but not to the lymph nodes. Treatment for stage II cancer is to 
excise the cancerous tissue and in most cases a colectomy. In addition to surgical excision, 
adjuvant chemotherapy may also be necessary. Stage III cancer is characterized by the invasion 
of the cancer to the surrounding lymph nodes. Treatment includes surgical resection and adjuvant 
chemotherapy and/or radiotherapy. The commonly used chemotherapies for stage III CRC are 
FOLFOX (5-FU, leucovorin, and oxaliplatin) or CapeOx (capecitabine and oxaliplatin). Stage IV 
cancer is characterized by the metastasis of the cancer to another organ. In many cases, CRC 
metastasizes to the lungs, liver, or distant lymph nodes. In some cases, surgery cannot be 
performed due to the large size of the tumors or the number of tumors. In this case, 
chemotherapy and radiotherapy are administered to extend the patient’s life. In other cases, the 
tumors in the colon and metastasized region (lung, liver, distant lymph nodes) can be resected 
and following resection, chemotherapy and radiotherapy are administered.  
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Figure 2: Stages of CRC. In stage I, the tumor is contained within the mucosa, submucosa, and 
muscle layers of the colon but does not penetrate the serosa layer. In stage II, the tumor grows 
and invades the serosa layer. In stage III, the tumor penetrates the serosa layer is is now 
growing outside of the colon and has spread to the surrounding lymph nodes. Finally, in stage 
IV, the tumor increases in size and metastasizes to distant organs such as the liver or lung. 
(Image Source Reference 9; Copyright: see appendix) 
 
1.1.5 Treatment of Colorectal Cancer 
In most cases, treatment of CRC starts with surgery to remove the polyps and affected 
colon, rectum, and lymph nodes 8,10.  In addition to surgical resection, some cases require 
additional treatments such as colostomies, radiofrequency ablation, or cryoablation. Figure 3 
shows the course of action for each stage. A colostomy is a procedure in which a portion of the 
colon is attached to an exit point in the abdomen where a pouch resides for waste to exit. This is 
often temporary to allow for the rectum to heal. In some cases where the cancer has metastasized 
to the liver or lungs, an ablation may be necessary. The two types of ablation currently in 
practice are radiofrequency ablation and cryoablation. Radiofrequency ablation is performed by 
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emitting a radio frequency to the tumor in order to heat it; cryoablation is the opposite in which 
the tumor is frozen. These techniques can be done during surgery or through the skin outside of 
surgery. The use of these techniques allow for minimal normal tissue damage, however, there is 
a risk of leaving some tumor behind.  
 
 
Figure 3: Treatment by CRC Stage. In stage 0 and I, the main line of defense is simply to 
remove the polyps. If the polyps are too numerous, then a colectomy may be considered. For 
stages II and III, a colectomy is the first step to remove the cancerous polyps and/or tumors. 
Following surgical removal, radiation and/or chemotherapy may be administered depending on 
the apparent aggressiveness of the cancer. In stage IV, a colectomy is performed to remove any 
tumors. Following surgery, as a first line of defense, radiation is administered along with 
chemotherapy. There are two general types of chemotherapy used for stage IV CRC, 
antiangiogenic and anti-EGFR. Depending on the biomarkers exhibited by the cancer, one or 
both of these types of chemotherapies will be administered. (Image Source Reference 11; 
Copyright: see appendix) 
 
 
Radiation therapy utilizes X-rays, gamma rays, and charged particles to kill cancer cells. 
Radiation may be used before surgery to reduce tumor size or after surgery to kill any remaining 
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cancer cells 12,13. There are two main ways of delivering radiation - external-beam or internal-
beam radiation. There are six main types of external-beam radiation therapy. 1) Intensity-
modulated radiation therapy (IMRT) aims to deliver different doses of radiation to different parts 
of the tumor. This technique reduces normal cell damage as the areas on the edges of the tumor 
where normal cells reside receive a lower dose of radiation than the middle of the tumor. This 
has proven effective in reducing the side effects. 2) Image guided radiation therapy (IGRT) uses 
CT scans during radiation delivery. These CT scans allow for precision of dosing according to 
the position and exact current size of the tumor. 3) Tomotherapy is a more advanced version of 
IGRT in which the imaging and radiation is from a single rotating device. This allows for even 
more control and precision than the IGRT. 4) Stereotactic radiosurgery (SRS) is used for small 
tumors with a well-defined edge. This technique delivers high doses of radiation to a small 
tumor. This requires very accurate imaging in order to reduce normal tissue damage. This 
technique is commonly used for brain or spinal tumors. 5) Stereotactic body radiation therapy 
(SBRT) is used for tumors residing outside the brain or spine. 6) Proton therapy uses protons 
instead of X-rays or gamma rays. Protons deliver their energy according to the Bragg peak in 
which the highest amount of energy is delivered at a certain point in their path rather than evenly 
distributing energy throughout the path as electromagnetic rays . In theory, proton therapy should 
reduce normal tissue damage.  
Internal-beam radiation or brachytherapy involves the delivery of radiation through 
radioactive seeds or pellets placed in the body with catheters, needles, or wires 12,13. This 
treatment can be temporary or permanent. There are two main types of internal-beam radiation. 
1) Interstitial brachytherapy involves the placement of the radioactive particles within the tumor. 
2) Intracavitary brachytherapy is the placement of the radioactive particles in a body cavity that 
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is near the tumor.  
 There are several types and classes of chemotherapy that treat CRC. Some of these 
chemotherapy drugs can be used alone or in combination with a targeted chemotherapeutic. 
Some common treatment regimens are fluorouracil (5-FU) with leucovorin (together named 
Wellcovorin), Wellcovorin with oxaliplatin and Wellcovorin with irinotecan 10,12,13. Some known 
targeted therapies are cetuximab, bevacizumab, or panitumumab; these targeted therapies can be 
used alone or in combination with the drugs mentioned. In general there are two types of targeted 
therapies: anti-angiogenesis and anti-epidermal growth factor receptor therapies. Anti-
angiogenesis therapies aim to inhibit the growth of blood vessels to the tumor to limit nutrients 
and starve the tumor. Bevacizumab or Avastin is used with patients with advanced CRC. This 
anti-angiogenesis therapy inhibits vascular endothelial growth factor (VEGF) to inhibit blood 
vessel growth. Regorafenib or Stivarga is another anti-angiogenesis therapy that is approved for 
patients with metastasized CRC. Anti-epidermal growth factor receptors aim to inhibit cell 
growth. Cetuximab or Erbitux is a chimeric antibody composed of mouse and human 
components. This drug is given to patients with metastasized CRC with wild type KRAS.   
Panitumumab or Vectibix is a human based monoclonal antibody. This anti-EGFR is also used 
with patients with metastasized CRC with wild type KRAS.  
 
1.2 RNA SEQUENCING 
 RNA sequencing (RNA-seq) is a method of high throughput, deep sequencing RNA 
either directly or indirectly through cDNA. RNA-seq aims to analyze the transcriptome at a 
given period of time, ie the time of RNA extraction 14. RNA-seq can detect all types of RNA 
include miRNA, lncRNA, snoRNA, rRNA, tRNA, etc. Additionally, it can detect alternative 
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splicing arrangements, differential expression of genes between two conditions, post-
transcriptional modifications, mutations, single nucleotide polymorphisms (SNPs), and gene 
fusions. Prior to the development of RNA-seq, microarray was the standard in studying 
transcriptomic elements. The microarray involves hybridization of the cDNA to a chip with 
immobilized DNA probes of known sequences. This was used to measure the expression of a 
sets of genes. The limitations of microarray are the chances of cross hybridization artifacts, poor 
quantification of low expressed genes, and prior knowledge of the sequences. In RNA-seq, the 
sequences do not need to be known, so novel genes could be identified with RNA-seq. 
To prepare the cDNA for RNA-seq, first total RNA is extracted, purified, quantified, and 
measured for integrity 14,15. Following, the RNA can be filtered to only include mRNA or it can 
be reverse transcribed as total RNA. Following cDNA synthesis, the cDNA is fragmented 
according to the sequencing machine ideals. Afterwards, the cDNA is sequenced by a next 
generation sequencer such as Illumina or Roche 454. This analysis is illustrated in Figure 4.  
In general, there are two approaches to analyze RNA-seq data which are genome-guided 
and de novo synthesis 14,15. The genome-guided approach uses a reference genome to map the 
transcripts to. This process starts by grouping the overlapping reads from each locus followed by 
creating a graph of all possible isoforms, and then settling on the individual isoforms. De novo 
assembly approach creates a transcriptome without a reference genome. This is done by 
primarily by locating overlapping sequences in the fragments, then forming the overlapping 
sequences into contiguous sequences (contigs), then by using the contigs, a scaffold is formed, 
and finally the gaps are filled within the scaffold and a unique gene or transcript is formed. 
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Figure 4: RNA Sequencing Schematic. 1) After RNA extraction and purification, the RNA 
molecules are fragmented. 2) The fragments are subjected to random priming to produce single 
stranded complementary DNA (sscDNA). 3) The sscDNA fragments are subjected to a second 
round of random priming to produce double stranded cDNA (dscDNA). 4) These fragments are 
selected based on size or number of base pairs. 5) The dscDNAs are sequenced in a sequencer. 
6) The sequences are converted to a fasta or fastq file for RNA Seq analysis by Tuxedo Suite 
Pipeline or similar pipelines. (Image Source Reference 16; Copyright: see appendix) 
 
1.3 Wnt Signaling and TGFβ Pathways  
 1.3.1 Wnt Signaling Pathway Overview 
 The Wnt signaling pathway is a vital process that is involved in every stage of 
development. The Wnt pathway controls cell proliferation, cell adhesion, and cytoskeletal 
arrangement 17–20. There are three variations of the Wnt pathway that controls each of these 
phenotypes: the canonical, noncanonical planar cell polarity (PCP), and noncanonical Wnt/Ca2+ 
pathways. The canonical pathway was first observed in mice in 1982 and five years later it was 
observed in Drosophila melanogaster. The Wnt pathways are crucial in the development of 
many organs such as, brain, eye, spinal cord, skin, teeth, heart, etc. In adulthood, the pathways 
are needed for tissue homeostasis, regeneration, and repair. Given its crucial nature, the Wnt 
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pathways are well studied in the instances of cancers. The canonical pathway is known to be 
dysregulated in a variety of cancers including CRC.  
The important players of the Wnt canonical pathway include: Wnt ligands, β-catenin 
(CTNNB1), G-protein Frizzled receptor (Fzd), low density lipoprotein receptor related proteins 
(LRP), Dishevelled (Dvl), and T-cell factor-lymphoid enhancer factor complex (TCF/LEF) 
17,18,20,21. The noncanonical pathways are also termed β-catenin independent pathways. Important 
players in the noncanonical PCP pathway are: Wnt ligands, Fzd, JNK, Dvl, RhoA, and ROCK2. 
The important players in the Wnt/Ca2+ pathway are: Wnt ligands, Fzd, Dvl, PLC, 
Calcium/Calmodulin Dependent Protein Kinase II (CAMKII), PKC, and Calmodulin. Shown in 
Figure 5, is a simplified version of the Wnt pathways. In the canonical pathway, Wnt is 
recognized by the intermembrane complex Fzd/LRP complex which recruits the destruction 
complex comprising of several proteins including Dvl, axin, APC, and GSK3B 17,18,20. This 
destruction complex, when recruited by the activation of Wnt/Fzd/LRP complex, can no longer 
target β-catenin for degradation. In turn, β-catenin accumulates and translocates to the nucleus 
and interacts with TCF/LEF complex to activate transcription of its target genes. In the PCP 
pathway, Wnt activates Fzd which activates a signaling cascade that starts with the activation of 
Dvl which activates RhoA and Ras. RhoA and Ras independently activate ROCK2 and JNK, 
respectively. ROCK2 and JNK are responsible for cytoskeletal rearrangement and cell polarity. 
Finally, in the Wnt/Ca2+ pathway, Wnt activates Fzd which activates Dvl. The activation of Dvl 
and its downstream targets (PLC, PLG) allow for the influx of calcium. The high concentration 
of calcium and the active form of Dvl activate CAMKII, PKC, and Calmodulin. CAMKII 
inhibits β-catenin action onto TCF/LEF in the nucleus, PKC activates CDC42 which promotes 
actin polymerization, Calmodulin promotes the translocation of NFAT to the nucleus which acts 
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as a transcription factor for genes important for the determination of cell fate and migration.  
  
 
Figure 5: Wnt Pathway Schematic. In the Canonical Pathway, the WNT ligand binds to the 
Frizzled receptor and causes a signal cascade which activates Dvl to inhibit the β-catenin 
destruction complex. This inhibition allows β-catenin to accumulate in the cytoplasm which is 
then translocates to the nucleus to activate the LEF/TCF transcription factor complex. This 
complex then activates transcription of the target genes. In the Wnt/Ca2+ pathway displayed in 
the middle, upon the binding of the WNT ligand to Frizzled, Dvl is activated. Dvl activates PKC 
and also promotes the influx of calcium. PKC then activates CDC42 and promotes migration. 
The influx of calcium activates CAMKII which activates the transcription factor family NFAT. 
NFAT promotes cell migration and cell fate. The PCP pathway displayed on the right, starts with 
the WNT ligand binding to the Frizzled receptor in which Dvl is activated and recruits RhoA and 
Ras. RhoA activates ROCK2 and Ras activates JNK. These two proteins are responsible for 
cytoskeletal rearrangement. (Image Source Reference 22; Copyright: see appendix) 
 
1.3.2 Wnt Signaling Pathway in Colorectal Cancer 
The Wnt pathway in CRC is known to have aberrant expression in all stages of CRC 
19,21,23–25. There are various mutations that account for the upregulation of Wnt in CRC. Two of 
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the most common mutations occur in the adenomatous polyposis coli gene (APC) and β-catenin 
20,23,25. Mutations in APC cause a loss of function of the protein. APC is a key component in the 
destruction complex which targets β-catenin. Mutations in APC can arise sporadically or from a 
hereditary illness, familial adenomatous polyposis (FAP) (Najdi Rani et al). Mutations in β-
catenin cause a loss of phosphorylation site in the N-terminus which is pivotal for the destruction 
complex to recognize, phosphorylate, and degrade β-catenin. The loss of this site, in turn, allows 
for constitutive signaling of the canonical Wnt pathway (Morin, Patrice J., et al).  
Other mutations that are common in CRC include mutations in other components of the 
destruction complex including Axin 1 and 2 26,27. Axin 1 and 2 are negative regulators of the Wnt 
pathway and are considered tumor suppressors. When mutated, these proteins cannot effectively 
degrade β-catenin, resulting in constitutive signaling. There are multiple reports of somatic 
mutations in Axin 1 and many reports of germ-line mutations in Axin 2. There are three germ-
line mutations in Axin 2: two of them cause a premature stop codon in exon 7 creating a 
truncated, nonfunctional protein, and the other mutation causes a missense in exon 5.  Moreover, 
not only have mutation been reported, but epigenetic silencing of Axin 1 and 2 are reported in 
CRC.  
Wnt inhibitory factor 1 (WIF1) is a Wnt antagonist and acts by binding to the Wnt 
ligands to prevent binding to the Fzd/LRP receptor complex 28,29. A report in 2015 in the 
Familial Cancer Journal, noted a mutation in WIF1 at amino acid 294 in which the mutation 
caused a cysteine to become a phenylalanine and was associated with higher cancer risk by 
promoting NAD synthesis 30. Additionally, a WIF1 mutation has been reported in Nail-Patella-
like Disorder in which a mutation in WIF1 may be a novel cause of this disorder 31. In this study, 
a nonsense mutation was observed which resulted in the complete loss of the N terminus which 
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inhibited its ability to be secreted.  
 Secreted Frizzled-Related Protein 4 (SFRP4) is a member of the SFRPs and is an 
inhibitor of the Wnt pathway and targets the WNT ligands 32,33. SFRPs contain a cysteine rich 
binding domain which gives SFRPs the capability to bind to Fzds. This results in a competitive 
binding with WNT ligands to bind to Fzd, additionally, SFRPs can bind directly with WNT 
ligands to inhibit their binding to Fzd, thus interfering with the Wnt pathway.  
In addition to common mutations in tumor suppressors, there are countless genes that are 
epigenetically modified to be expressed or repressed. In most cases, these genes are tumor 
suppressors such as WIF1, Dickkopf 1 (DKK1), CDKN2B, or transcription factors such as 
CDX2 34. 
 
1.3.3 Transforming Growth Factor β Pathway Overview 
The transforming growth factor β pathway is involved in cell proliferation, cell 
differentiation, apoptosis, extracellular matrix remodeling, immune functions, invasion, 
metastasis, and cellular homeostasis 35–38. The TGFβ pathway has tumor suppressor roles and is 
often dysregulated in cancers due to mutations, deletions, or dysregulated regulatory factors of 
the components involved. There are more than 40 members that belong to the TGFβ pathway 
including activin/inhibin subfamily, bone morphogenetic proteins (BMPs), and others 39. The 
TGFβ superfamily of proteins contain three members: TGFβ1, TGFβ2, and TGFβ3. These three 
proteins share ~70% homology.  
There are two types of TGFβ pathways: Smad-dependent and Smad-independent 35,38,39. 
In the Smad-dependent pathway, the TGFβ ligands interact with the TGFβ receptors (TGFβR), 
activin receptor, or BMP receptor which then causes a signal transduction within the receptor 
24 
 
bearing cell. This signal transduction cascade results in the recruitment and phosphorylation of 
Smad2 and Smad3. Phosphorylated Smads 2 and 3 bind with Smad4 and translocate to the 
nucleus to interact with a number of transcription factors to regulate target gene expression.  
In the Smad-independent pathways, the activation of TGFβ causes activation in a number 
of other related pathways such as the p38 kinase pathway, MAPK pathway, Wnt PCP pathway, 
mTOR,pathway and PI3K/Akt pathway (Figure 6) 35,38,39. 
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Figure 6. The Various TGFβ Pathways. TGFβ and its receptor starts various signal 
cascades. Overall, the TGFβ pathway signals for EMT through various intermediate molecules. 
Through PI3K/Akt, TGFβ promotes cell growth and EMT. Through RhoGTPases, TGFβ 
promotes EMT, migration, and invasion. Through Smads, TGFβ promotes tumor suppression 
and tumor prevention. Through p38/JNK, TGFβ promotes EMT and apoptosis. Through MAPK, 
TGFβ promotes EMT. (Image Source Reference2; Copyright: see appendix) 
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One of the many outcomes of the TGFβ pathway cell cycle arrest (Figure 7) 35,38,39. TGFβ 
inhibits the cell cycle at G1 phase by inducing cyclin D kinase inhibitors: CDKN2B, CDKN1A, 
CDKN1B via Smad and and transcription factors Sp1 and FoxO. CDKN2B binds to the CDK4/6 
complex which displaces CDKN1A and CDKN1B which allows CDKN1A to bind to CDK2-
cyclin A/E complexes and CDKN1B to directly inhibit G1 progression. Additionally, TGFβ 
downregulates the oncogene, c-MYC and ID transcription factors through Smad and E2F4 and 
E2F5. The inhibition of c-MYC allows for the upregulation and activity of CDKN2B and 
CDKN1A to induce G1 phase arrest. The inhibition of the ID transcription factors allow for the 
upregulation of CDKN2A which also induce G1 phase arrest.  
Figure 7: TGFβ and Cell Cycle Inhibition Pathway. The induction of TGFβ signals for 
cell cycle arrest by inhibiting c-MYC and inducing CDKN2B (p15), CDKN1A (p21), and 
CDKN1B (p27) through the Smad-dependent pathway. The inhibition of c-MYC prevented its 
oncogenic capabilities of cell cycle progression. The induction of p15 allowed for the removal of 
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p21 and p27 from CDK4 and 6. This allows for p15 to bind to CDK4 and 6 to induct G1 arrest. 
The displacement of p21 and p27 frees p21 to bind to CDK2-Cyclin A/E complex which inhibits 
its ability to promote G1 progression. The freedom of p27 allows it to directly inhibit G1 
progression. (Image Source Reference 39; Copyright: see appendix) 
 
 
1.3.4 TGFβ Pathway in Colorectal Cancer 
TGFβ exhibits a dual role in cancer as it shows tumor suppressive and tumor promoting 
capabilities. In colorectal cancer, several plays of the TGFβ pathway are mutated. TGFβR3 is 
often mutated and results in a truncated final protein 39. Additionally, it was found that Smad2 
mutations are common in CRC which may be due to deletions, frameshift mutations, nonsense or 
missense mutations. The mutation of Smad2 results in its inability to form a complex with 
Smad4, inhibit the activation of Smad-mediated transcription, or increase the expression of Smad 
repressors. Moreover, the increased expression of Smad7, reported in pancreatic, endometrial, 
and thyroid follicular cancers, antagonize the TGFβ pathway.  
In the case of epithelial to mesenchymal transition (EMT), the increased expression of the 
TGFβ pathway leads to the promotion of EMT 36,37,39,40. TGFβ represses its downstream target, 
microRNA-200 (miR-200), which leads to the increased expression of the target of miR-200, 
ZEB2. The expression of ZEB2 decreases the expression of E-cadherin which leads to cell 
migration and invasion. 
The TGFβ pathway has been shown to be an indicator of prognosis 39. TGFβ pathway has 
been shown to regulate telomerase reverse transcriptase (TERT), responsible for immortalization 
of cancer, by negatively regulating its transcription through Smad3 and the transcription factor 
E2F1.  
1.3.5 CD82 
CD82 belongs to the tetraspanin family of proteins and is a tumor metastasis suppressor 
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that has been found to inversely correlate with cell invasion, motility, metastasis, and cell 
survival 41,42. CD82 is involved in various pathways including the TGFβ and Src kinase-
dependent pathways. CD82 was first discovered in 1995 as a tumor metastasis suppressor in rats 
for the treatment of prostate cancer 43.  Since then, recent studies have reported metastasis 
suppression capabilities in bladder, breast, hepatocellular, and pancreatic cancers 41,42,44,45. CD82 
acts with accordance with integrins and receptor tyrosine kinases, however, its exact mechanism 
is unclear.  
CD82 is regulated on three levels: epigenetic, transcriptional, and post translational 
44,46,47. On the epigenetic level, HOTAIR, a lncRNA, targets CD82 for methylation and thus 
silencing. On the transcription level, there are various factors that induce the transcription of 
CD82 at the promoter region including, JunB, ATF3, AP1, AP2, NF-kB and p53 46. 
Additionally, CD82 is upregulated in hypoxic conditions via HIF-1a to promote metastasis in the 
innermost layer of the tumor micro environmet47.On the post translational level, CD82 is 
recruited to the endoplasmic reticulum for N-glycosylation and degradation by ubiquitin ligase 
gp78. A summary of the factors affecting CD82 function is illustrated in Figure 8. 
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Figure 8: The Regulation and Outcomes of CD82. CD82 has several regulatory factors 
and can regulate a variety of processes. The increase of cAMP in the cell signals for ERAD 
which signals for gp78 to post translationally degrade CD82. When CD82 is expressed it can 
inhibit cell motility and invasion, activate tumor cell death, activate tumor cell senescence, and 
activate exosomal discharge. In turn, exosomal discharge inhibits β-catenin/reptin. (Image 
Source Reference 47; Copyright: see appendix) 
 
 
1.4 Long Non Coding RNA 
 1.4.1 Introduction to lncRNAs 
Long noncoding RNA (lncRNAs) is a new discovery in the field of biology and medicine 
48–50. LncRNAs are RNA molecules that are greater than 200 bp, polyadenylated, and lack an 
open reading frame. They are a part of the noncoding RNA (ncRNA) class that includes 
microRNAs (miRNAs), small nuclear RNA (snoRNA), small interfering RNA (siRNA), etc. The 
non-protein coding region of DNA is ~70-90% of the total genome, however, very little is 
known about ncRNAs. The current research being done is investigating the ncRNAs to show that 
they not “junk” as once believed. These ncRNAs have an immense effect on regulation, 
epigenetic modifications, splicing, etc. 
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There are roughly 32,000 ncRNAs transcribed versus 21,000 proteins transcribed 50. 
LncRNAs are of interest since these RNAs can fold into 3-dimensional structures in which may 
interact with transcription factors, histones, DNA, RNA, and other biomolecules to create duplex 
or triplex structures. LncRNAs have numerous functions including: chromatin modification, 
direct transcriptional regulation, RNA processing events such as splicing, post-translational 
modifications, modulation of microRNA, and gene silencing through endogenous siRNA 
production. These functions are illustrated in Figure 9 below. 
  
31 
 
 
Figure 9: Long Non Coding RNA Functions. A) LncRNAs can act as a transcriptional 
activator by recruiting RNA polymerase. B) LncRNAs can also act as a transcriptional repressor 
by sequestering RNA polymerase which prevents RNA polymerase from transcribing DNA. C) 
LncRNAs can act as a transcriptional guide in which the lncRNA can guide the RNA polymerase 
to the lncRNA target gene. D) LncRNAs can act as a scaffold by recruiting proteins to perform 
chromatin modifications. E) LncRNAs can edit RNA via the ADAR deaminase. F) LncRNAs can 
promote splicing in conjunction with splicing factors. G) Some microRNAs are coded within a 
lncRNA and therefore some lncRNAs can harbor microRNAs for later use. H) Some lncRNAs can 
have complementary sequences to microRNAs so that the microRNAs bind to the lncRNAs 
instead of their mRNA targets, therefore these lncRNAs effectively sequester microRNAs. I) 
LncRNAs can have complementary binding sites similar to microRNAs; however, instead of 
sequestering microRNAs, these lncRNAs bind directly to the mRNA target, thus blocking the 
action of the microRNAs. J) LncRNAs can degrade RNA with the use of Staufen. The lncRNA-
Staufen complex recruits an exosome which degrades the target RNA. K) LncRNAs can increase 
transcription efficiency by increasing ribosomal efficiency. (Image Source Reference 51; 
Copyright: see appendix) 
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It is difficult to characterize lncRNAs because of their range in size, structure, location, 
and function. Based on the location of the lncRNA genomic target, lncRNAs can be classified as 
cis or trans shown in Figure 10 49,52. Cis acting lncRNAs are act on neighboring genomic 
locations and trans acting lncRNAs are act on a variety of genomic locations. LncRNAs can be 
classified based on location: sense, antisense, bidirectional, intronic, and intergenic, shown in 
Figure 11 48,49.  Sense lncRNAs overlap one or more exons on the same strand. Antisense is the 
opposite of sense; it overlaps one or more exons on the opposite strand. Bidirectional transcripts 
have the same start site as a protein coding gene. Intronic lncRNAs originate from the introns of 
a gene. Intergenic lncRNAs arise from regions between two genes. 
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Figure 10: Cis and Trans acting lncRNAs. A) Cis acting lncRNAs are lncRNAs that are 
transcribed and act in the same region. B) Trans acting lncRNAs are transcribed and act in a 
distinct genomic locations. (Image Source Reference 51; Copyright: see appendix) 
 
 
Figure 11: The origins of lncRNAs. There are five types of lncRNAs based on their origin in the 
genome: Intergenic, bidirectional, sense, natural antisense, and intronic. Intergenic lncRNAs 
arise from regions between two genes. Bidirectional lncRNAs arise from bidirectional 
promoters. Sense lncRNAs are lncRNAs that arise in the sense direction of the gene and contain 
exons of the parent gene. Natural antisense lncRNAs arise from the antisense direction of the 
parent gene and contains exons. Intronic lncRNAs can be categorized into two types: intronic 
antisense or intronic sense. Intronic antisense lncRNAs arise from the introns in the antisense 
direction. Intronic sense lncRNAs are sense lncRNAs from the intronic regions. (Image Source 
Reference 53; Copyright: see appendix) 
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Most importantly, lncRNAs show a great potential in the field of cancer pathology. As 
more information concerning lncRNAs develops, the better cancer pathology, dysregulated 
pathways, and progression can be understood. 
The most notable lncRNAs have a genome wide effect which include Xist, HOTAIR, 
MALAT-1, ANRIL, and ZEB1 and ZEB2 3,49,50,54,55. These lncRNAs, when dysregulated, can 
cause hallmark cancer phenotypes such as epigenetic modifications, dysregulation of apoptotic 
genes, dysregulation of cell cycle genes, alternative splicing, protein localization, stem cell 
pluripotency, etc.  
 
1.4.2 Molecular Mechanisms 
The molecular mechanisms of lncRNAs can be classified into four groups according to 
what the lncRNA acts as: as a signal, as a decoy, as a guide, and as a scaffold as shown in Figure 
12 56,57. Since lncRNAs are translated by RNA polymerase II like mRNA, lncRNAs can show 
cell type specific expression and respond to stimuli to echo the changing dynamic of the cell 
environment. Since most lncRNAs alter chromatin state, if the lncRNAs are known, the 
chromatin state can be deduced.  
One example of a signal lncRNA is Xist 56,57. Xist enacts on the X chromosome for gene 
imprinting in order for the cell to only transcribe one of the two X’s. Xist is polyadenylated and 
capped and is only transcribed by the X chromosome to be inactivated 58. Xist inactivates its 
target by coating the X chromosomes. This acts as a signal for recruitment of chromatin 
remodeling factors. Other lncRNAs may function as signals for DNA damage, pluripotency, 
reprogramming, enhancing transcription, and repeated or abundant transcription.  
 When lncRNAs act as decoys, they act as an effector that results in no effect on its target, 
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inhibiting function of the target56–58 . LncRNAs can act as decoys for microRNAs, splicing 
factors, and proteins. In the case of lncRNA PANDA, binds to NF-YA to inhibit the expression 
of apoptotic genes. PANDA has been shown to be expressed during DNA damage and influences 
cell survival. When PANDA is depleted or knocked out, a high frequency of apoptosis was 
observed. In order to repress apoptosis, some cancers overexpress PANDA.  
 The third mechanism lncRNAs may undergo is guiding. The lncRNA will bind to its 
protein target and guide the protein to a location either in cis or in trans 57. In cis, lncRNAs can 
stimulate chromatin changes cotranscriptionally as they are bound to RNA polymerase II or 
lncRNAs can bind complementarily to small regulatory RNAs. In trans, lncRNAs bind to DNA 
to create a heteroduplex (RNA: DNA) or triplex (RNA:DNA:DNA). Both mechanisms result in 
changing the chromatin structure. HOTAIR acts in trans by targeting, recruiting, and guiding 
PRC2 to act on the histones to methylate the target genes 3,57,59.  
 The last mechanism type is lncRNAs acting as scaffolds. These lncRNAs often possess a 
variety of domains to bind to different targets 57. TERC, a telomerase RNA component, is a 
lncRNA that acts as a scaffold for telomerase. TERC works in combination with TERT 
(telomerase reverse transcriptase) and TERRA (lncRNA with repeated telomeric sequences) 
48,56,57,60. TERC has two functions: 1) to act as a template for TERT and 2) to act as a scaffold for 
protein subunits to bind. TERC is associated with sustaining and regulating the length of the 
telomeres. Telomere length is directly related to cellular aging and senescence.  
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Figure 12: Molecular mechanisms of lncRNAs. There are four main molecular mechanisms for 
lncRNAs. LncRNAs can act as a decoy, scaffold, guide, or enhancer. LncRNAs can act as a 
decoy by binding to a protein which prevents the protein from performing its original action.  As 
a scaffold, lncRNAs can recruit proteins which together perform a distinct function such as 
chromatin remodeling. As a guide, lncRNAs can guide transcription factors or RNA polymerases 
to the target gene. As an enhancer, lncRNAs can use its scaffolding abilities to perform gene 
enhancement such as demethylation of a gene to promote transcription. (Image Source 
Reference 61; Copyright: see appendix) 
 
1.4.3 HOX Transcript Antisense RNA  
 HOX transcript antisense RNA (HOTAIR) is one of the first known lncRNAs. HOTAIR 
is comprised of ~2 kb and 6 exons 3,50,57,59. It originates from the antisense strand of the HOXC 
gene and is a trans-acting lncRNA and has a variety of targets (Figure 13). In general, HOTAIR 
alters the epigenetic modifications on chromatin shown in Figure 9. HOTAIR targets, recruits, 
and guides the Polycomb Repressive Complex 2 (PRC2). PRC2 silences its targets through its 
histone methyltransferase activity. Additionally, HOTAIR can recruit the lysine specific 
demethylase 1 (LSD1) which demethylates histone H3 at lysine 4 to un-silence or activate its 
37 
 
target. HOTAIR has the capability to silence and un-silence genes concurrently by binding to 
PRC2 at the 5’ end and LSD1 at the 3’ end.  
Recent studies have found that HOTAIR is a major component in many cancers due to its 
ability to promote mobility, proliferation, apoptosis, invasion, aggression, metastasis, and 
stemness of the cells 3,50,57,59. HOTAIR may be a likely biomarker. A meta-analysis was done in 
2014 by Cai et al, in order to evaluate the association between HOTAIR and lymph node 
metastasis 59. They found that higher levels of HOTAIR correlated with high incidence of 
metastasis.  
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Figure 13:HOTAIR mechanism of action. HOTAIR is located on chromosome 12 in the HOXC 
gene cluster between exons 11 and 12 and is in the antisense direction. HOTAIR acts as a 
scaffold for the recruitment of the Polycomb repressive complex 2 (PRC2) and the lysine-specific 
histone demethylase 1 (LSD1) complex. These two complexes have opposing roles: PRC2 
methylates target gene promoters and silences expression while the LSD1 demethylates 
previously silenced genes to promote their transcription. (Image Source Reference 3; Copyright: 
see appendix) 
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1.4.4 Urothelial Carcinoma Associated 1  
Urothelial Carcinoma Associated 1 lncRNA is 1.4 kb in length and was first discovered 
in bladder cancer was found to be associated with tumorigenesis and invasion 62–64. It was also 
found as a tumor promoter in breast, colorectal, gastric, and esophageal squamous cell 
carcinoma. A recent study completed in 2016, found that in CRC cells, the upregulation of 
UCA1 was associated with the uncontrolled growth through the p53/p21 signaling pathway 65. In 
oral squamous cell carcinoma (OSCC), it was found that UCA1 may also have a relationship 
with the Wnt signaling pathways 65. In UCA1 knockdown experiments, it was found that the Wnt 
pathway was significant decreased as well as its downstream targets were downregulated, 
however, the mechanism of how UCA1 modulates the Wnt pathway is unresolved. One report 
shows that the overexpression of UCA1 was correlated with at least 2-fold expression of two 
Wnt pathway members: WNT5A and FZD5 64, however, the mechanism of action is unknown.  
There is little information on the structure or mechanism of action of UCA1. What is 
known is that UCA1 is strongly associated with cancer progression, cell proliferation, apoptosis, 
and chemoresistance 66–70. In CRC, UCA1 has been shown to be markedly upregulated shown in 
many studies suggesting that UCA1 may be a candidate for the use of a prognostic marker, 
diagnosis, or as a therapeutic target 71. 
 
 1.4.5 Colorectal Neoplasia Differentially Expressed  
 Colorectal Neoplasia Differentially Expressed (CRNDE) is a lncRNA that is known to be 
differentially expressed in colorectal cancer 54,72,73. This lncRNA was originally found in CRC 
with a high expression. It is located on chromosome 16 on the antisense strand of the gene IRX5. 
CRNDE contains 10 kb, 5 exons, and has been shown to be alternatively spliced 54. CRNDE is 
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also found to be overexpressed in various cancers including, ovarian, pancreatic, liver, kidney, 
and leukemia. CRNDE has been shown to regulate neuronal differentiation, gametogenesis, and 
cancer progression. Some recent studies have suggested that CRNDE may also be involved in 
chromatin remodeling; however, more investigation is needed for confirmation 72. Since CRNDE 
is normally involved in brain and gamete development, it is found to be tissue-specific and 
temporally regulated 73. In adulthood, CRNDE expression levels are little to none in most tissue 
types.  
The exact mechanism of CRNDE is not yet elucidated. One study as shown that CRNDE 
may negatively regulate microRNA 186 (miR-186) in human glioma stem cells (GSCs) 74. In this 
study, the overexpression of CRNDE was shown to decrease miR-186 and increase cell 
proliferation, migration, invasion, and decrease apoptosis. While the overexpression of miR-186 
had the opposite effects of decreasing cell proliferation, migration, invasion, and increasing 
apoptosis rates. The mechanism of action of these lncRNAs are not yet elucidated, however, 
there are several correlations that have been made. In addition to establishing correlations 
between lncRNAs and vital cancer promoting genes, the investigation of genetic variations in 
lncRNAs will facilitate understanding of the mechanisms of actions and downstream effects.  
1.5 Single Nucleotide Polymorphisms  
 Single nucleotide polymorphisms (SNPs) are mutations, insertions, or deletion of a single 
nucleotide 75–77. SNPs have been known to be the underlying reason for various cancers and 
diseases. SNPs can be categorized by the location: protein-coding, non-protein coding, and 
intergenic. The consequence of a SNP can be categorized as synonymous or nonsynonymous 
with nonsynonymous SNPs having two subcategories: missense and nonsense mutations. 
Missense mutations result in a different amino acid than the original sequence and nonsense 
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mutations result in an early stop codon which creates a truncated protein. SNPs in the non-
protein coding and intergenic regions do not cause amino acid changes, however, these SNPs 
may cause changes in gene splicing, transcription factor binding, and regulatory element 
detection. There are various known SNPs linked with colorectal cancer including SNPs in 
microRNAs and genes in the interferon signaling pathway 75–77.  
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CHAPTER 2: HYPOTHESIS AND OBJECTIVES 
 2.1 Hypothesis  
Stage IV colorectal cancer exhibits the standard metastasized characteristics of invasion, 
uncontrolled cell proliferation, deletions, mutations, and dysregulation of various pathways. 
However, more information needs to be uncovered about the underlying mechanisms and the 
role of lncRNAs to fully understand the scope and environment of metastasized colorectal 
cancers. 
Therefore, it is hypothesized that the interplay of lncRNAs, inhibitors, activators and 
mutations in these players that are involved in cell proliferation pathways may have a greater 
role in metastasized colorectal cancer than thought before and may be therapeutic targets. 
 2.2 Objectives 
1. To determine differentially expressed genes in colorectal cancer 
2. To determine a vital differentially expressed pathway in colorectal cancer 
3. To predict a novel dysregulation between differentially expressed protein coding genes 
and long non coding RNAs in the differentially expressed pathway 
4. To determine possible SNPs in the genes involved.  
5. To suggest a pathway between long non coding RNAs and protein coding genes 
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CHAPTER 3: MATERIALS AND METHODS 
 
 3.1 Data Source and Sample Selection 
The data was obtained from the Gene Expression Omnibus (GEO) where the data is 
stored with the accession number GSE560760. The data was produced by Seon-Kyu Kim et al, a 
research group in South Korea in 2014 78. Their published paper is entitled, “A nineteen gene-
based risk score classifier predicts prognosis of colorectal cancer patients” and was published in 
the Molecular Oncology Journal, Volume 8, Issue 8, December 2014.  
 The study used matched tissue samples from 18 patients who had primary CRC cancer 
and liver metastasis. Three sample tissue types were extracted from each patient: primary CRC 
tissue, liver metastatic tissue, and normal colon tissue. The authors extracted total RNA, 
assembled a sequencing library, and ran RNA sequencing with Illumina 2000. All patients were 
treated in the Asan Medical Centre in Seoul, South Korea between May 2011 and February 
2012.  
3.2 RNA-seq Data Processing  
In this current study, five paired normal and cancer RNA datasets were analyzed. The 
reads were paired-end reads and were processed by splitting the ends and trimming and filtering 
poor quality reads. The processed reads were then assessed for quality using FastQC v 0.11.2 
(available online at http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) 79.  
  
3.3 RNA-seq Alignment and Differential Expression  
After the initial processing, the Tuxedo Suite Package was used in order to determine the 
differentially expressed genes from the processed RNA sequences from paired normal and 
cancerous tissues (Figure 14). First, the processed reads were aligned to the human genome using 
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Bowtie v.2.2.6.0 (http://bowtie-bio.sourceforge.net/index.shtml) and TopHat v.2.1.0 
(https://ccb.jhu.edu/software/tophat/index.html) 80. Then the sequences were assembled into 
transcripts using CuffLinks v2.2.1 (http://cole-trapnell-lab.github.io/cufflinks/install), then the 
transcripts for all replicates are merged together by CuffMerge v2.0.2 (http://cole-trapnell-
lab.github.io/cufflinks/cuffmerge/) 81,82. Differential expression of the transcripts was determined 
by using CuffDiff v2.2.2 (http://cole-trapnell-lab.github.io/cufflinks/cuffdiff/), and finally, the 
differential expression was visualized using the R package, CummeRbund v3.2.3 
(http://bioconductor.org) 83.  
Bowtie is a short sequence aligner that is used for quick read alignment to the reference 
genome. Additionally, Bowtie indexes the genome using the Burrows-Wheeler transform (BWT) 
algorithm 84. Indexing allows for faster analysis in TopHat.   
TopHat uses the index created by Bowtie to align the reads on the genome with splice 
junctions 80. This algorithm is optimized to align short reads with little error and is able to 
identify novel splice sites. 
Cufflinks is used for transcript assembly, abundance estimation, and differential 
expression 85. Cufflinks estimates the abundance of the transcripts based on the number of 
supporting transcripts while excluding any biases from sequence library preparation.  
Cuffmerge is used to merge the Cufflinks transcripts from each replicate into one 
composite file 82. This step is not vital for the pipeline, however, it allows for fluid final 
differential expression analysis.  
Cuffdiff is used to assembly transcripts and to find the differential expression of genes, 
transcription start sites, splicing, and promoters 83. This is the final step that renders the 
differential expression of the two conditions. These results are visualized in CummeRbund, an R 
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program.  
CummeRbund uses the output from Cuffdiff and creates a database of the results and 
describes their relationship and significance 85. This is then used to visualize the data in the form 
of boxplots, scatterplots, volcano plots, heatmaps, and others.  
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Figure 14: Tuxedo Suite Pipeline Workflow. The starting components for the Tuxedo Suite are 
the raw sequences or reads of the two conditions in question and a reference genome. These 
three components are entered to Bowtie which aligns the reads to the genome and also indexes 
the genome for faster computing. TopHat uses the aligned reads and maps these to the genome. 
Cufflinks uses these mapped reads and assembles the associated transcripts. Cuffmerge 
combines the normal and cancer transcripts to one composite file. Cuffdiff measures the 
differential expression between the two conditions and gives the final output of complete list of 
differentially expressed genes (DEGs). Finally, CummeRbund, an R program, is used to visualize 
these results.  
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3.4 Differential Gene Analysis 
 The workflow to analyze the differentially expressed genes is shown in Figure 15. To 
classify the DEGs, the PANTHER database (v 11.1) was used 86. PANTHER is available online 
at http://pantherdb.org/about.jsp. PANTHER is an acronym for Protein ANalysis THrough 
Evolutionary Relationships and is a classification tool designed for analysis of high-throughput 
results. PANTHER is a part of the Gene Ontology Phylogenetic Annotation Project and contains 
13,096 protein families, divided into 78,442 functionally distinct protein subfamilies. The genes 
are classified in four ways: family and subfamily, molecular function, biochemical process, and 
pathway. Three sets of genes were analyzed: all DEGs, upregulated genes, and downregulated 
genes.  
 lncRNA2Target (v 1.2) is a webtool which finds the lncRNA that targets the gene of 
interest or it can find what genes a particular lncRNA targets 34. LncRNA2Target is available 
online at https://www.lncrna2target.org/. The evidence supporting the results are from literature. 
Each result has the link to the supporting report. Using the results from PANTHER, a pathway 
and its DEG were identified. Focusing on the WNT proteins and WNT inhibitors, a table of 
associated lncRNAs was established. 
 The Integrative Genomics Viewer (IGV) (v 2.3.97) was used to visualize transcripts and 
sequences of the data 87. IGV is a desktop tool and is available for download at 
http://software.broadinstitute.org/software/igv/. The input data was derived from TopHat which 
is the aligned and mapped transcripts. IGV can be used to search for specific genes to visualize 
the number of transcripts in a locus and also to visualize mutations such as deletions, insertions, 
and SNPs.  
 Once a SNP was found in IGV, the database of SNPs (dbSNP) was used to determine if 
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the SNP was previously recorded. dbSNP is a public online database maintained by NCBI and is 
available at https://www.ncbi.nlm.nih.gov/snp/ 88.   
 The SNPs were then further evaluated for function and consequence with FuncPred. 
FuncPred is a SNP prediction webtool provided by the NIH and is available at 
https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html 89.   
 Any potentially novel SNPs were examined for predicted function via DeepSEA 90. 
DeepSEA uses deep learning algorithms to determine predicted binding sites in variant 
sequences.  
 
Figure 15: DEG analysis workflow. After obtaining the DEGs from the Tuxedo Suite Pipeline, 
the genes were entered into PANTHER for pathway enrichment. Activators and inhibitors from 
the most enriched set of genes were entered into the lncRNA2Target database to determine if 
these genes had associated lncRNAs. Once a complete set of activators, inhibitors, and 
associated lncRNAs were gathered, they were visualized in IGV to determine any genetic 
variants. Any genetic variants or SNPs were further investigated in NCBI SNP database, 
FuncPred database, and if there were any potentially novel SNPs, DeepSEA predicted software 
was used to obtain information on the consequence. With this information combined with 
literature reviews, a novel connection could be made.  
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CHAPTER 4: RESULTS 
4.1 Metadata and Data Statistics  
 Prior to starting the Tuxedo Suite pipeline analysis, each of the samples was analyzed for 
its number of reads, GC content, and gender. These results are shown in Table 1. The samples 
analyzed were normal colon mucosa and paired primary CRC from male patients from South 
Korea 78.  
Table 1: Description of Normal and Cancer Datasets. Each sequence dataset has an 
identifier prefix of ‘N’ or ‘C’ signifying Normal or Cancer samples, respectively. All normal 
samples are paired with cancer samples. Each sample has its corresponding number of reads.  
 
Sample Identifier Tissue Type Gender Stage Number of Reads 
N1 Normal Colon Mucosa Male - 54,992,947 
N2 Normal Colon Mucosa Male - 23,653,357 
N3 Normal Colon Mucosa Male - 67,611,184 
N4 Normal Colon Mucosa Male - 50,662,612 
N5 Normal Colon Mucosa Male - 38,477,372 
C1 Primary CRC Male IV 64,924,130 
C2 Primary CRC Male IV 56,433,491 
C3 Primary CRC Male IV 43,648,154 
C4 Primary CRC Male IV 58,551,634 
C5 Primary CRC Male IV 58,368,923 
 
 
4.2 Differentially Expressed Genes 
After analyzing the datasets with the Tuxedo Suite pipeline analysis, the DEGs were 
visualized via CummeRbund. Differentially expressed genes were identified with two filters: p-
value and fold change. Genes with a p-value of 0.05 or less and a fold change of less than -0.5 or 
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greater than +0.5 were considered significant. The summarized output of the Tuxedo Suite 
pipeline analysis is shown in Table 2. Table 2 shows several variables identified in the data 
including the total number of open reading frames, number of promoters, number of transcription 
starts sites, number of splicing sites, and others. The number of differentially expressed genes 
was 5,303 (Table 3). Also included in Table 3 is the range of fold change values and the number 
of up- and downregulated genes. The scatter plot shows the distribution of the genes under both 
conditions, normal and cancer conditions (Figure 16). The volcano plot is used to visualize the 
number of significant versus insignificant genes (Figure 17).  
 
Table 2: Tuxedo Suite Pipeline Output. This table shows the overall differential 
expression output. There were 57,176 total genes, 335,486 isoforms, 142,942 TSS, 82,459 CDS, 
57,176 promoters, and 142,942 splicing sites. 
 
Total Open Reading Frames 
(ORFs) 
57,176 
Isoforms 335,486 
Transcription Start Sites (TSS) 142,942 
Coding DNA Sequence (CDS) 82,459 
Promoters 57,176 
 
 
 
Table 3: Differentially Expressed Gene Summary. The number of differentially expressed 
genes with a p-value of less than or equal to 0.05 and with a fold change value less than or equal 
to -0.5 and greater than or equal to +0.5 were 5,303. The fold change values ranged from 5.676  
to +10.738. The number of upregulated genes were 3,070. The number of downregulated genes 
were 2,233.  
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Differentially Expressed Genes, P value ≤ 0.05 5,303 
Range of Log2 Fold Values  -5.676  to +10.738 
Number of Upregulated Genes 3,070 
Number of Downregulated Genes 2,233 
 
 
 
 Figure 16: Scatter Plot of Genes Expressed in Normal Colon Mucosa vs Genes Expressed 
in CRC. The scatter plot maps the genes expressed in both conditions and in this scatter plot 
there is a roughly linear relationship between most of the genes expressed in both conditions. 
The data points that are outside of the linear portion are the genes that are differentially 
expressed.  
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Figure 17: Volcano Plot showing the Relationship between the Normal and Cancer 
Samples by cummeRbund. Using the p-value cut off of less than or equal to 0.05 and the fold 
change cut off of greater than or equal to 0.5 and less than or equal to -0.5, the biological and 
statistical significance were determined. The data points above the red line show the biological 
and statistical significant genes.  
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4.3 Pathway Enrichment Analysis 
 Pathway enrichment analysis was done using the Panther database. This analysis 
generated a pie chart with the names of the pathways that the DEGs were involved in and the 
percentage of genes involved in each pathway (Figure 18). Pathway enrichment was done three 
times, once with all of the DEGs, once with only the upregulated genes, and once with only the 
downregulated genes. In all of the DEGs, the Wnt pathway was the most enriched set 
representing 4.9% of the total genes. In the upregulated genes/ORFs, the Wnt pathway 
represented most enriched set with 7.2%. Finally, when analyzing the downregulated 
genes/ORFs, the Wnt pathway was the fifth most enriched set with only representing 2.5% of the 
genes.  
 
Figure 18: Pathway enrichment analysis by Panther DB. A) This pie chart represents the 
pathway enrichment for all the differentially expressed genes and ORFs, up- and 
downregulated. The top 5 enriched pathways are listed with their corresponding percentages. 
The Wnt pathway was the pathway the most enriched with 4.9% of the genes representing it. B) 
This pie chart represents the pathway enrichment for only the upregulated genes. The top 5 
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enriched pathways are listed with their corresponding percentages. The Wnt Pathway is at the 
top and represents 7.2% of the genes. C) This pie chart represents the pathway enrichment for 
the downregulated genes. The top 5 enriched pathways are listed with their corresponding 
percentages. The Wnt Pathway ranks at the fifth most enriched pathway with its genes 
representing 2.5% of the downregulated differentially expressed genes.  
 
The differentially expressed Wnt pathway genes were identified and a literature review 
was done on the Wnt pathway and the Wnt pathway DEGs. Tables 4, 5, and 6 show the Wnt 
pathway genes, the inhibitors, and the targets of the Wnt pathway and their associated fold 
change, respectively, which confirms that the Wnt pathway is active.  
 
Table 4: Differentially Expressed Wnt pathway genes. The table is organized from lowest 
level to highest fold change. A majority of the genes are upregulated as expected from the 
Panther analysis. Several Wnt and Frizzled (Fzd) proteins are upregulated which initiate the 
Wnt pathway. 
 
Wnt Pathway Genes Fold Change 
PRKACB -1.497 
PRKCBA -1.387 
TCF21 -1.383 
WNT9A -1.383 
MAPK10 -1.247 
FZD1 -0.862 
RILP -0.796 
CSNK2A1 0.593 
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AXIN1 0.615 
CTNNB1 0.626 
PRICKLE4 0.833 
TCF3 0.860 
FZD6 0.943 
LRP11 0.974 
LRP3 1.041 
GPC4 1.058 
PPP2R3B 1.279 
CCND1 1.429 
WNT3 1.503 
AXIN2 1.650 
WNT11 1.996 
CDK8 2.237 
WNT5A 2.261 
FZD10 2.677 
LEF1 2.804 
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LRP8 3.319 
NKD1 3.353 
NKD2 4.913 
WNT2 5.722 
MMP7 6.032 
  
 
 
Table 5: Differentially Expressed Wnt pathway inhibitors. This table is organized from lowest to 
high fold change. Note: all inhibitors are upregulated with DKK4 having an infinite fold change, 
this is due to the undetected expression in the normal samples.  
 
 
Wnt Inhibitors Fold Change 
SFRP4 2.121 
APCDD1 2.384 
DKK2 4.342 
WIF1 5.165 
NOTUM 6.812 
DKK4 INF/Undetected in 
Normal Samples 
 
 
Table 6: Differentially Expressed Target Genes of the Wnt Pathway: The table is organized from 
lowest to highest fold change. All of the target genes are upregulated except for ATOH1 which is 
expected to be downregulated when the Wnt pathway is promoted.  
 
 
 
Gene Fold Change 
ATOH1 -1.114 
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PLAUR 0.842 
VEGF 1.069 
BIRC5 1.266 
CD44 1.311 
CCND1 1.429 
MET 1.512 
AXIN2 2.050 
MYC 2.355 
NRCAM 2.580 
LEF1 2.804 
CLDN 4.631 
MMP7 6.032 
 
 
 
4.4 Long Non Coding RNA Target Analysis 
 
In order to find what lncRNAs target a particular gene and vice versa, a database named 
lncRNA2Target was utilized. The inhibitors and WNT ligands were focused on (Tables 7 and 8). 
WIF1 and SFRP4 specifically target the WNT ligands.  By target analysis, HOTAIR was found 
to target and silence WIF1. This result is supported by a study completed in 2013 by Xiao-Song 
Ge et al in which they found that HOTAIR directly methylates and silences WIF1 in esophageal 
squamous cell carcinoma and other groups have verified this relationship in bladder, gastric, and 
pancreatic cancers 91–93.  
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Table 7: lncRNA2Target results for DE Wnt ligands. The differentially expressed Wnt 
ligands were entered into lncRNA2Target db in order to find associated lncRNAs. WNT9A has 
no known associated lncRNAs. lncRNA CRNDE is known to activate WNT2 and WNT3. TUG1 is 
known to target WNT11, however TUG1 is not DE in this dataset. UCA1 is known to target and 
activate WNT5A.  
 
WIF1 Target  Fold Change P value Associated lncRNA Fold Change P value lncRNA Action 
WNT9A -1.503 0.00075 None - - - 
WNT3 1.503 5.00E-05 CRNDE 3.227 0.0032 Positively Regulates 
WNT11 1.996 5.00E-05 TUG1 - - Positively Regulates 
WNT5A 2.261 5.00E-05 UCA1 5.542 5.00E-05 Positively Regulates 
WNT2 5.722 0.0019 CRNDE 3.227 0.0032 Positively Regulates 
 
 
 
Table 8: lncRNA2Target Database results for DE Wnt inhibitors. The differentially 
expressed Wnt inhibitors were entered into lncRNA2Target database to find associated lncRNAs. 
CRNDE is known to negatively regulate SFRP4. MALAT1 is known to negatively regulate 
APCDD1, however MALAT1 is not differentially expressed in this dataset. TUG1 is known to 
positively regulate DKK2, however TUG1 is not differentially expressed. HOTAIR is known to 
negatively regulate WIF1. There are no known lncRNAs associated with NOTUM or DKK4. 
 
Wnt Inhibitors Fold Change P value Associated lncRNA Fold Change P Value lncRNA Action 
SFRP4 2.121 0.00185 CRNDE 3.227 0.0032 Negatively Regulates 
APCDD1 2.384 5.00E-05 MALAT1 - - Negatively Regulates 
DKK2 4.342 5.00E-05 TUG1 - - Positively Regulates 
WIF1 5.165 5.00E-05 HOTAIR 5.198 0.03785 Negatively Regulates 
NOTUM 6.812 0.00115 None - - - 
DKK4 INF 0.00175 None - - - 
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4.5 Differentially Expressed HOTAIR Target Genes 
HOTAIR has many known target genes, and its effect can either be to unsilence or to 
silence the target gene. There are 11 known targets for HOTAIR in which HOTAIR un-silences 
five and silences six. Table 9 shows a list of the target genes that were differentially expressed 
with their associated expected and observed effect, along with the expression and p values. There 
were two genes that acted opposite to the expected effect, WIF1 and CD82.  
 
Table 9. Differential Expression of HOTAIR Target Genes. A list of HOTAIR target genes 
was obtained from lncRNA2Target database. This list was cross referenced with the DEGs and a 
table was generated showing the expected and observed effect with the corresponding expression 
value and p value. WIF1 and CD82 are two targets that did not show the expected effect. 
 
 
Gene Expected Effect Observed 
Effect 
Log Fold Change P Value 
MMP1 ↑ ↑ 4.706 5.0E-5 
MMP3 ↑ ↑ 5.54 5.0E-5 
MMP9 ↑ ↑ 1.425 5.0E-5 
VEGFA ↑ ↑ 1.06 0.0004 
WIF1 ↓ ↑ 5.165 5.0E-5 
CD82 ↓ ↑ 1.05 0.00075 
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4.6 IGV SNP Analysis  
 Normal and cancer datasets were loaded into IGV and the following genes were 
investigated: WIF1, SFRP4, WNT2, WNT3, WNT5A, CRNDE, UCA1, HOTAIR, and CD82. 
Eleven SNPs were found in five of the genes: WIF1, SFRP4, WNT5A, CD82, and UCA1; no 
consistent abnormalities were found in the others. Ten out of eleven SNPs were previously 
recorded and one appears to be novel in CD82 since this SNP was not found in SNPdb. Of the 
nine known SNPs, four were synonymous mutations, two were 3’ UTR variants, two were 
missense variants, and one was an intron variant (Table 10). 
 
Table 10: Observed SNPs in CD82, SFRP4, UCA1, WIF1, and WNT5A. All genes of 
interest were analyzed by IGV for abnormalities in the transcripts, CD82, SFRP4, UCA1, WIF1, 
and WNT5A showed consistent SNPs throughout the samples. Nine out of the ten observed SNPs 
were previously recorded and found in dbSNP, one SNP in CD82 is novel at location 
chr11:44,619,242 with a frequency in 100% of the samples.  
 
Gene Observed SNP Location Accession No. SNP Name Consequence 
Cancer Replicates 
Containing SNP (/10) 
CD82 chr11:44,619,242 NA CD82-N  10 
 chr11:44,619,090 rs7107335 CD82-S1 Synonymous 4 
 chr11:44,618,718 rs11541053 CD82-M1 Missense 10 
SFRP4 chr7:37,907,562 rs1802073 SFRP4-M1 Missense 7 
 chr7:37,906,899 rs1052981 SFRP4-3 3'UTR 5 
 chr7:37,912,124 rs1132553 SFRP4-S1 Synonymous 8 
 chr7:37,914,238 rs1132552 SFRP4-S2 Synonymous 10 
UCA1 chr19:15,834,304 rs7258210 UCA1-IV Intron Variant 7 
WIF1 chr12:65,120,486 rs7301320 WIF1-S1 Synonymous 4 
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WNT5A chr3:55,466,974 rs669889 WNT5A-3 3'UTR 7 
 
 
4.7 FuncPred SNP Results 
 FuncPred prediction software was used to determine the function of the SNPs. The 
resulting consequence of the SNP including changes in transcription factor binding sites (TFBS), 
splicing, microRNA binding sites, and possible phenotype (Table 11).  
 
Table 11: FuncPred Results on Previously Known Observed SNPs. The nine known SNPs 
were analyzed by FuncPred for determination of possible consequences. UCA1-IV affects a 
transcription factor binding site (TFBS), CD82-M1, CD82-S1, SFRP4-S1, SFRP4-S2 affect a 
splicing mechanism, SFRP4-3 and WNT5A-3 is in a miRNA binding region, and SFRP4-M1 
shows that it is possibly damaging but without a reason, and WIF1-S1 shows no adverse 
consequence.  
 
SNP rs TFBS Splicing miRNA nsSNP Stop Codon Polyphen Reg Potential Conservation 
CD82-
M1 rs11541053 
-- 
Y 
-- Y -- Benign 0.494976 0.99 
CD82-
S1 rs7107335 
-- 
Y 
-- -- -- -- 0.446336 0.94 
UCA1-3 rs7258210 Y -- -- -- -- -- NA 0 
SFRP4-
3 rs1052981 
-- -- 
Y 
-- -- -- 0.032177 0.002 
SFRP4-
S1 rs1132552 
-- 
Y 
-- -- -- -- 0.227926 0.801 
SFRP4-
S2 rs1132553 
-- 
Y 
-- -- -- -- 0.350342 1 
SFRP4-
M1 rs1802073 
-- -- -- Y -- Possibly damaging 0.405909 0.028 
WIF1-
S1 rs7301320 
-- -- -- -- -- -- 0.294625 0.979 
WNT5A
-3 rs669889 
-- -- 
Y 
-- -- -- 0.122852 0 
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4.8 Prediction of Possible SNP Consequence using DeepSEA 
Using DeepSEA prediction software, the coordinates of the variant were entered along 
with the nucleotide change in a VCF file. A graph was generated comparing the possible 
chromatin features and log fold change values. The chromatin feature with the highest log fold 
change value was ZBTB7A.  
 
 
Figure 19: Prediction Graph for Potentially Novel CD82-N. Generated by DeepSEA, this 
graph represents all possible chromatin features that may bind to the site of the SNP. Ranking by 
log2 fold change, the blue dot on the far right and top most represents the chromatin feature with 
the highest fold change, ZBTB7A. ZBTB7A was predicted to have a log2 fold change value of 
0.311. 
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4.9 CDKN2A and CDKN2B Downregulation  
  
 By DEG analysis and literature review, the TGFβ pathway has been shown to be 
implicated in colorectal carcinoma. In this dataset, the TGFβ pathway is shown to be upregulated 
by the increased fold change in the members of the pathway (Table 12).  
 
Table 12: Differentially Expressed TGFβ Pathway Genes. Of the three known TGFβ 
receptors, only TGFβR1 is differentially expressed with a fold change of 0.575. The TGFβ 
inducer (TGFβI) is upregulated with a fold change of 1.532. miR-200 is upregulated with a fold 
change of 1.429 and its target, ZEB2 is repressed with a fold change of -1.131. CDKN2A and 
CDKN2B are downregulated. Most of the BMP proteins are downregulated with the exception of 
BMP7 which is upregulated. BMPER is a BMP inhibitor which may account for the BMP 
downregulation. Finally, All of the Smad proteins are downregulated and differentially 
expressed except for Smad2. Smad2 did not meet the cutoff stipulations to be considered as 
biologically and statistically significant.  
 
TGFβ Pathway Genes Fold Change P Value Significant? 
TGFβR1 0.575 0.02455 Yes 
TGFβR2 - - - 
TGFβR3 - - - 
TGFβI 1.532 5.00E-05 Yes 
miR-200 1.429 0.0001 Yes 
ZEB2 -1.131 5.00E-05 Yes 
CDKN2A -2.266 5.00E-05 Yes 
CDKN2B -2.266 5.00E-05 Yes 
BMP2 -1.102 5.00E-05 Yes 
BMP3 -2.355 5.00E-05 Yes 
BMP5 -1.629 0.00105 Yes 
BMP6 -1.801 0.0389 Yes 
BMP7 1.296 0.00085 Yes 
BMPER 2.11899 0.00105 Yes 
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SMAD2 -0.5799 0.0858 No 
SMAD3 -0.5475 0.04255 Yes 
SMAD4 -0.6879 0.01085 Yes 
SMAD7 -0.8065 0.0032 Yes 
 
 
 
The CDK inhibitors CDKN2A and CDKN2B are known as a tumor suppressor and is 
frequently deleted in cancers and colorectal cancer. In this dataset, CDKN2A and CDKN2B fold 
change was -2.266. The downstream targets are upregulated (Table 13) indicating a regulation 
mechanism to negatively regulate CDKN2A and CDKN2B.  
 
Table 13: Differential Expression of the Downstream Targets of CDKN2A and CDKN2B. When 
upregulated, the downstream targets of CDKN2A and CDKN2B are downregulated. With the 
downregulation of CDKN2A and CDKN2B transcripts, it is expected for the downstream targets 
are upregulated which is demonstrated in this dataset.  
 
Downstream Target Log2 Fold 
CDK4 1.183 
CDK6 0.666 
E2F1 1.898 
E2F3 1.170 
CCND1 1.429 
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CHAPTER 5: DISCUSSION 
 
5.1 The Wnt Pathway has the Greatest Number of Differentially Expressed Genes 
 The Wnt pathway can be divided into three subtypes: Wnt/β-catenin or canonical 
pathway, non-canonical planar cell polarity pathway (PCP), and non-canonical Wnt/Calcium 
pathways 18,20,32. These subtypes promote cell proliferation, cell polarity, and cell adhesion and 
migration, respectively. The Wnt pathway is upregulated in several cancers including colorectal, 
breast, liver, gastric cancers among others.   
 The canonical pathway also referred to as the Wnt/β-catenin pathway is dependent on the 
accumulation β-catenin in the nucleus which activates the transcription factor complex, 
TCF/LEF 18,20,32. This complex promotes the transcription of the Wnt target genes: MYC, 
CCND1, MMP7, AXIN2, VEGF, MET, and others which were upregulated in this dataset. These 
genes promote the cell cycle progression and proliferation.  
 The PCP pathway promotes cell polarity and cytoskeletal rearrangement 18,20,32. It is β-
catenin independent and is thus categorized as a non-canonical pathway. This pathway activates 
ROCK2 which is responsible for cell adhesion and cytoskeletal rearrangement. Additionally, this 
pathway also targets the JNK pathway. ROCK2 targets and phosphorylates several genes 
including ADD1, BRCA2, CNN1, EZR, and others in which some of these targets are 
differentially expressed. The JNK pathway genes include MAPK8, MAPK9, and MAPK10 94. 
This pathway plays an essential role in apoptosis and cell proliferation.  The target genes of this 
pathway include MMP3, CCND1, JUNB, FOSL1, FOSL2, FOSB, cFOS, and ATF2 18. 
 The Wnt/Calcium pathway promotes cell adhesion and migration by targeting NFAT, 
NEMO, and CDC42 20,25,32. NFAT is activated through the activation of PLC which allows for 
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the influx of calcium. Calcium activates calmodulin which in turn activates NFAT. NFAT is a 
family of transcription factors which regulate cell survival, cell proliferation, migration, 
invasion, and angiogenesis 95. NEMO which inhibits β-catenin/TCF function. CDC42 is a 
GTPase and is responsible for tissue separation which in turn promotes cell migration 20.  
Pathway enrichment showed that the Wnt pathway was the most enriched gene set in all 
of the DEGs. In the downregulated pathway enrichment results, the Wnt pathway genes was 
ranked number five; the pathway with the greatest number of genes expressed is cytokine and 
chemokine mediated inflammation or the NFĸB pathway. Previous studies showed a crosstalk 
between the Wnt and NFĸB signaling pathways 96–99. Furthermore, the relationship between the 
Wnt pathway and the NFĸB pathway is shown to be highly dependent on cellular context. In the 
dataset, it appears that the Wnt pathway is negatively regulating the NFĸB pathway. In the 
dataset, the Wnt pathway represents the most genes in the downregulated gene set. It has been 
shown that the Wnt pathway can negatively regulate the NFĸB pathway through the 
accumulation of β-catenin. β-catenin forms a complex with RelA and p50 which is responsible 
for facilitating DNA binding with NFĸB. In turn, NFĸB is unable to transcribe its target genes. 
This relationship is consistent with research done on colon cancer cell lines 97–100. 
5.2 Lack of Epigenetic Silencing of WIF1 and CD82 by HOTAIR  
 When lncRNA2Target was used, the targets of HOTAIR were found and crossed 
referenced with the DEG list. Of the differentially expressed targets, all showed the expected 
expression pattern when HOTAIR is expressed except for WIF1 and CD82. WIF1 and CD82 are 
expected to be downregulated in the presence of HOTAIR; however, in this dataset WIF1 and 
CD82 are upregulated at 5.165 and 1.05, respectively.  
  HOTAIR epigenetically silences its targets through the binding, recruitment, and guiding 
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of Polycomb repressive complex 2 (PRC2) 59,101,102. The catalytically active subunit of the PRC2 
is differentially expressed; however, the two remaining subunits are not differentially expressed. 
They are, however, expressed in both conditions.  
 A recent study showed that HOTAIR is able to work independently of the PRC2 in a 
breast cancer cell line 101. By the use of forceful overexpression of HOTAIR, subtle 
transcriptomic changes were observed. Additionally, the study found that by the use of artificial 
tethering of HOTAIR to chromatin, it showed transcriptional repression was observed but not 
with the use of the PRC2.  
WIF1 is a proliferation inhibitor and CD82 is a metastasis inhibitor 17,25,28,44,45. When 
WIF1 and CD82 are expressed, the expected phenotypes are that of normal tissue homeostatic 
growth. These two genes, WIF1 and CD82, were found to carry SNPs. WIF1 has a single 
synonymous SNP in 40% of the replicates while CD82 has three SNPs, one novel (CD82-N), 
one synonymous (CD82-S1), and one missense (CD82-M1) in 10/10, 4/10, and 10/10 of the 
replicates, respectively. According to FuncPred, SNPs CD82-S1 and CD82-M1 of CD82 cause a 
change in splicing site that causes either a splice site enhancer or silencer region. Additionally, 
CD82-M1 is a nonsynonymous SNP and by FuncPred, it is also a benign mutation. These SNPs 
may be the cause of which may play a role in its inability to be silenced by HOTAIR.  
Whether HOTAIR utilizes the PRC2 to silence its targets or not, it would be expected 
with such a high expression of HOTAIR that WIF1 and CD82 would be silenced, however, the 
SNPs in WIF1 and CD82 may be preventing their silencing.  
5.3 Functional Prediction of Potentially Novel SNP in CD82 
The potentially novel SNP, CD82-N (location: chr11:44,619,242) was predicted to create 
a binding site with ZBTB7A. ZBTB7A or Pokemon has two domains, a zinc finger at the C 
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terminus and a BTB domain at the N terminus 103,104. The zinc finger is used for DNA 
recognition and the BTB domain is used for homo- or heterodimerization to interact with 
proteins. ZBTB7A is known to be deleted or mutated in a large subset of cancers as well as 
amplified in small cell lung cancer 104–106. It is a known oncogene and is involved in 
adipogenesis, osteogenesis, and oncogenesis. The primary functions are to act as a transcription 
factor to suppress glycolysis through repressing genes in the glycolytic cycle and to suppress p53 
expression through the repression of ARF. Additionally, ZBTB7A has also been reported to 
regulate transcription, cytoskeletal dynamics, ion channel assembly and gating, and protein 
targeting for ubiquitination.  
ZBTB7A was not differentially expressed in this dataset, however, this may be due to any 
loss of RNA during the RNA extraction process and/or filtering low quality reads. If ZBTB7A 
were to be expressed in the cellular context studied, then ZBTB7A may be repressing CD82 
function through this SNP. If so, then metastasis would not be suppressed and CRC would be 
able to progress and metastasize to the liver as known by the patient histories. Since it was not 
differentially expressed in this dataset, further investigation is required to determine binding and 
role.  
5.4 Interplay Between SFRP4 and CRNDE 
By the use of lncRNA2Target, it was found that lncRNA CRNDE negatively affects 
SFRP4, the mechanism by which CRNDE accomplishes this is unknown. In this dataset, 
CRNDE and SFRP4 are expressed at 3.228 and 2.121, respectively, clearly indicating another 
factor disrupting this relationship. By IGV analysis, it was found that SFRP4 carries four SNPs 
in the cancer samples. SFRP4-S1 and SFRP4-S2 were synonymous (rs1132553, rs1132552), 
SFRP4-M1 was nonsynonymous (rs1802073), and SFRP4-3 was in the 3’UTR (rs1052981). 
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SFRP4-S1 and SFRP4-S2 were found to cause changes in splicing site that may cause a splice 
site enhancer or silencer, SFRP4-M1 was found to be possible damaging but the mechanism of 
how this could be is not elucidated, and SFRP4-3 was found to have a miRNA binding site. By 
this analysis, it can be assumed that the SNPs play a role in the inhibitory function of SFRP4, its 
regulation by CRNDE and/or miRNAs, and splicing in which contributes to the tumorigenesis of 
CRC.  
5.5 The Interplay Between WIF1 and UCA1 to Inhibit or Activate WNT5A 
Since, WIF1-S does not cause any structural abnormalities that would inhibit the function 
and there are no known post-translational modifications that would degrade WIF1, WIF1 in 
theory would still be active to inhibit its Wnt ligand targets. The lncRNA2Target database, 
showed that lncRNA UCA1 positively regulates WNT5A (Table 6). A possible defense 
mechanism of cancer would be to upregulate a competitor of WIF1 to ultimately activate the 
Wnt pathway. The mechanism by which UCA1 positively regulates WNT5A is unknown; 
however, it is possible that WIF1 and UCA1 may compete with each other to inhibit or activate 
WNT5A, respectively (Figure 20). This mechanism would explain why although WIF1 is highly 
expressed, the Wnt pathway is able to transcribe and activate its targets.  
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Figure 20. Possible Competition Mechanism between WIF1 and UCA1 to Inhibit or 
Activate WNT5A. With the upregulation of HOTAIR and its inability to silence WIF1, it is 
possible that there may be a mutation in the WIF1 promoter that is preventing the recognition of 
WIF1 by HOTAIR, which is observed in this dataset. This would subsequently cause an 
upregulation of WIF1 which would be able to inhibit its targets, WNT5A. WNT5A and its 
associated lncRNA UCA1 are upregulated. There may be a competition between WIF1 and 
WNT5A associated lncRNA, UCA1. UCA1 is known to positively regulate WNT5A. So, with the 
upregulation of HOTAIR, WIF1, WNT5A, UCA1, and the Wnt pathway as a whole, UCA1 may 
be competing with WIF1 to positively regulate WNT5A and subsequently the Wnt pathway.  
 
5.6 The Interplay Between WIF1 and CRNDE to Inhibit or Activate WNT2 and 
WNT3 
For the WNT2 and WNT3 ligands, it was found using lncRNA2Target that lncRNA 
CRNDE positively regulates WNT2 and WNT3; however, the mechanism of which CRNDE 
positively regulates WNT2 and WNT3 is unknown. Because the WIF1 protein would remain 
unchanged, it is possible that CRNDE would also compete with WIF1 to activate or inhibit 
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WNT2 and WNT3 (Figure 21). This mechanism would explain why the Wnt pathway is 
upregulated.  Figure 22 shows a complete overview with all of the genes involved with SNPs 
denoted.  
 
 
Figure 21: Possible Competition Mechanism between WIF1 and CRNDE to Inhibit or 
Activate WNT2 and WNT3. With the upregulation of HOTAIR and its inability to silence WIF1, it 
is possible that there may be a mutation in the WIF1 promoter that is preventing the recognition 
of WIF1 by HOTAIR, which is observed in this dataset. This would subsequently cause an 
upregulation of WIF1 which would be able to inhibit its targets, WNT2 and WNT3. WNT2 and 
WNT3 and its associated lncRNA CRNDE are upregulated. There may be a competition between 
WIF1 and CRNDE. CRNDE is known to positively regulate WNT2 and WNT3. So, with the 
upregulation of HOTAIR, WIF1, WNT2, WNT3, CRNDE, and the Wnt pathway as a whole, 
CRNDE may be competing with WIF1 to positively regulate WNT2 and WNT3 and subsequently 
the Wnt pathway. 
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Figure 22: Comparison of Pathway Outcomes between Normal and Cancer Conditions. 
On the left is a schematic of events when HOTAIR is expressed. When HOTAIR is expressed, 
WIF1 and CD82 are silenced thus the Wnt Pathway and metastatic pathways are active. In this 
case, on the right, when HOTAIR is expressed, the SNPs in WIF1 and CD82 may be preventing 
HOTAIR from silencing. WIF1 and SFRP4 are competing with CRNDE and UCA1 to inhibit or 
activate the WNT ligands and in this case, CRNDE and UCA1 are ultimately activating the WNT 
ligands for the Wnt pathway to be active. Additionally, CRNDE may be negatively regulating 
SFRP4 which may be a contributing factor to the inability of SFRP4 to inhibit the WNT ligands.    
 
 
5.7 CDKN2A and CDKN2B Methylation in South Korean Colorectal Cancer 
Patients 
A study was conducted to assess the methylation patterns of Finnish and Egyptian 
colorectal cancer patients 107. The study showed that there are many features of CRC that are 
universal across both ethnic types such as the dysregulation of p53. The study also found that 
there are some features of CRC that are specific to the ethnic origin of the patients. For example, 
microsatellite instability was highly prevalent in Egyptian CRC patients compared to Finnish 
patients. This study also found that previous research conducted that focused on CDKN2B was 
mainly in Western patient cohorts residing in Europe of the United States, and that there was no 
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strong correlation between the methylation of CDKN2B and colorectal cancer. The methylation 
of CDKN2B was found to be a distinct feature of the Egyptian population of CRC.  In another 
study done on a Chinese cohort, CDKN2B methylation was found at a rate of 68% 108. The study 
hypothesized that the difference may be due to genetic and environmental predisposition of the 
Egyptian population. 
The downregulation of CDKN2A and CDKN2B was observed. It is likely that this 
downregulation is due to methylation, as this is a common consequence in cancer. This 
methylation pattern may be specific to Eastern populations as seen in studies in Egyptian and 
Chinese cohorts. Since the dataset studied is derived from South Korean patients, it is likely that 
the environmental factors and genetics of the South Koreans may have contributed to the 
methylation of CDKN2A and CDKN2B.  
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CHAPTER 6: CONCLUSIONS AND FUTURE PERSPECTIVES  
 6.1 Conclusions 
 Using a fold change cutoff of greater than 0.5 and less than -0.5 and a p value cut off of 
less than 0.05, there are 5,303 differentially expressed genes in South Korean male patients with 
stage IV colorectal cancer. The Wnt pathway is known to have aberrant expression in colorectal 
cancer 18,20,25,32. The Wnt pathway can be divided into three subtypes: Wnt/β-catenin or canonical 
pathway, non-canonical planar cell polarity pathway, and non-canonical Wnt/Calcium pathways. 
These subtypes regulate cell proliferation, cell polarity, and cell adhesion and migration, 
respectively.   
 Among the upregulated Wnt pathway inhibitors were Wnt Inhibitory Factor 1 (WIF1) 
and Secreted Frizzled Related Protein 4 (SFRP4). WIF1 is known to bind to the Wnt ligands and 
inhibits its binding to the Frizzled and Frizzled/LRP cell surface receptors 18,20,25,32. SFRP4 is 
known to either bind with the WNT ligands or Frizzled to prevent the downstream cascade and 
activation of the Wnt Pathway. WIF1 has a fold change value of 5.165 and SFRP4 has a fold 
expression of 2.121. With an expression this significantly upregulated, it would be expected that 
the Wnt pathway and the target genes would be downregulated; however, the pathway genes and 
their targets are also upregulated.  
HOTAIR is known to epigenetically affect the expression of many genes utilizing PRC2 
and LSD1 to methylate and de-methylate targets, respectively 50,91,101,102. All of the differentially 
expressed targets of HOTAIR were expressed as expected when there is a high expression of 
HOTAIR except for WIF1 and CD82. HOTAIR is known to silence WIF1 and CD82; however, 
these genes were upregulated in this dataset.  
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 The lack of silencing by HOTAIR may be due to the SNPs observed in WIF1 and CD82. 
These SNPs may be preventing HOTAIR and the Polycomb repressive complex 2 (PRC2) from 
recognizing and silencing WIF1 and CD82.  
 Urothelial cancer associated 1 (UCA1) is a lncRNA where its expression has been 
correlated with poor prognosis in CRC, increased chemoresistance in urothelial cancer, and 
promotion of proliferation, metastasis, and tumorigenesis through various pathways including the 
Wnt signaling pathways 62–67,70. LncRNA UCA1 was found to positively regulate WNT5A. So, 
UCA1 may be competing with WIF1 to ultimately activate WNT5A. The mechanism by which 
UCA1 positively regulates WNT5A is unknown. The SNP found in UCA1, UCA1-3 is in a 
transcription factor binding site which may enhance UCA1 effectiveness; the exact mechanism 
and clinical consequence is unknown. The SNP found in WNT5A, WNT5A-3 is in the 3’UTR 
and was found to alter a microRNA binding site. Because miRNAs target genes for degradation, 
this specific alteration may be preventing the miRNAs from recognizing WNT5A for 
degradation. 
Colorectal Neoplasia Differentially Expressed (CRNDE) is a lncRNA where its 
expression is associated with poor prognosis, chemoresistance, cell proliferation, tumorigenesis, 
and stemness 54,72–74,109. Along the same terms, lncRNA CRNDE has been found to positively 
regulate WNT2 and WNT3. A similar mechanism may also be the case; CRNDE may be 
competing with WIF1 to ultimately activate WNT2 and WNT3. There were no SNPs or 
abnormalities in these genes and the mechanism of how CRNDE positively regulates WNT2 and 
WNT3 is unknown.  
The Wnt pathway is ultimately upregulated shown by the upregulation in the Wnt 
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pathway proteins and its targets despite the upregulation of its inhibitors. This incongruity may 
be due to a competition between WIF1 and CRNDE and UCA1 to positively regulate the WNT 
ligands. The SNPs in CD82 may be hindering its function as a tumor metastasis suppressor and 
its ability to be silenced by HOTAIR. The potentially novel SNP, CD82-N, was predicted to 
create a binding site for ZBTB7A which would repress CD82 function and, in turn, allow for 
metastasis to be uninhibited by CD82. Additionally, it seems that UCA1 and CRNDE are 
ultimately activating WNT5A, WNT2, and WNT3 in order for the Wnt pathway to proceed.  
The limitations of this study are the small sample size with only 5 matched normal and 
cancer datasets, all of the sample datasets were from South Korean males, and the limited 
computational and memory capacity available. Ideally, all 18 available sample datasets would be 
analyzed and compared with Eastern (ie Egyptian and Chinese) and Western cohorts to validate 
these results. 
 6.2 Future Perspectives 
 Because of the small sample size of this study, future studies are headed to confirm the 
mutations in the WIF1, SFRP4, WNT5A, UCA1, and CD82 by DNA sequencing of South 
Korean male stage IV colorectal patients. Additionally, functional assays should be conducted to 
determine the efficiency of the Wnt pathway in the presence of WIF1, SFRP4, UCA1, and 
CRNDE. Although these players are highly expressed at the RNA level, there may be post-
transcriptional and post-translational modifications that are not shown by this analysis. Little is 
known about the mechanism of action of lncRNAs UCA1 and CRNDE. Further investigation 
should delve into the functions of these lncRNAs in order to understand their precise role in the 
Wnt pathway. Once the roles for UCA1 and CRNDE are elucidated, they may be potential 
therapeutic or diagnostic targets. Inhibiting UCA1 and CRNDE may allow for WIF1 to 
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effectively inhibit the Wnt pathways, this would decrease cell proliferation, cell polarity, and 
migration. Lastly, more investigation is needed for the mechanisms of the remaining 
differentially expressed inhibitors found in this dataset: DKK2, DKK4, APCDD1, and Notum. 
The full elucidation of the mechanisms and pathways of the inhibitors in the Wnt pathway would 
be a powerful tool against stage IV colorectal cancer. This information would be vital for the 
development of therapeutic targets. 
It is clear that the Wnt pathway has a complex mechanism for regulation. The genes 
discussed may be candidates for therapeutic targets once the detailed mechanism of action is 
elucidated. LncRNAs are multifaceted and can regulate genes on all levels, so it is important to 
understand the key lncRNAs in the Wnt pathway and in all stages of colorectal cancer in order to 
develop personalized and efficient therapy. Rapid screening, diagnosis, and point of care tests are 
becoming a necessity. Once the mechanisms of actions of UCA1 and CRNDE are elucidated and 
the discrepancy of the remaining inhibitors is explained, the serum, saliva, and/or urine levels of 
these players and their correlation to the stages of CRC may lead to rapid screening and 
diagnosis. With the knowledge of the interplay of lncRNAs and their targets, noninvasive early 
detection of CRC is in the near future.  
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